MDBH Earnings

MDBH reported its earnings on 2025-03-31, showcasing a revenue of 0.00 against an estimate of , resulting in a 0% surprise. The EPS was 2.88, surpassing the expected 0 by 0%. The stock experienced a 2.28% price change on the earnings day and a -6.65% change over the next five days, reflecting market reactions to the results.

Following MDBH's earnings announcement on 2025-03-31, the stock price moved by 2.28% on the day of the release. Over the subsequent five days, it saw a -6.65% change. Historically, MDBH's stock price tends to shift by an average of -0.37% in the 10 days leading up to earnings and -16.02% in the 10 days following, providing insight into potential market.

For , analysts estimate MDBH's annual revenue to reach undefined, while the EPS is projected at undefined. These estimates reflect recent revisions, with revenue estimates revised downward by -14.86% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between MDBH's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for were revised downward by -14.86%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, MDBH's stock price typically moves by -0.37% in the 10 days before its earnings and -16.02% in the 10 days after. For the upcoming earnings, analysts expect an EPS of undefined and revenue of undefined.

The earnings call presents a mixed picture with potential positive catalysts like the HeartBeam FDA approval and promising partnerships, but also highlights significant risks such as macroeconomic uncertainties, execution risks, and distribution challenges. The financial health shows moderate cash burn and strategic investments, yet the unclear guidance on PatentVest's spin-out and dilution concerns for eXoZymes add uncertainty. The Q&A session reveals management's reluctance to provide concrete details, further tempering sentiment. Thus, the overall impact on stock price is expected to be neutral.